ClinicalTrials.gg
Active, not recruitingNCT06540144Updated Nov 6, 2026

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

A Phase 3 interventional study of rozanolixizumab in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Active, not recruiting at 9 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Now Active, not recruitingNo longer in Taiwan+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
10th of 10
13 · median 67
Started
2024
with 1 other
Phase 3
7 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
9 of 10
UCB Biopharma SRL

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 7th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Generalized Myasthenia Gravis
  • gMG
  • rozanolixizumab
  • pediatric
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study participant must meet one of the following:

  • Study participant completed MG0006 according to the protocol
  • Study participant completed the MG0006 Treatment Period and has a worsening of generalized myasthenia gravis (gMG) symptoms in the Observation Period of MG0006

Exclusion criteria

Exclusion Criteria:

  • Study participant met any mandatory withdrawal or mandatory permanent medicinal product (IMP) discontinuation criteria in MG0006 or permanently discontinued IMP
  • Study participant has a known to any components of the IMP or other neonatal Fc receptor (FcRn) drugs
  • Study participant has any laboratory abnormality that, in the opinion of the Investigator, is , has not resolved at Baseline, and could jeopardize or compromise the study participant's ability to participate in this study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    rozanolixizumab

    Study participants will receive pre-defined doses of rozanolixizumab. Each treatment cycle in each Treatment Period (TP) consists of 6 subcutaneous (sc) administrations of rozanolixizumab at 1-week intervals. Each Treatment Period will be initiated upon the discretion of the Investigator based on the medical needs of the study-participant.

    Drug: rozanolixizumab

Interventions

  • rozanolixizumab solution for injection

    Also known as: UCB7665

06

What researchers measure

Primary outcomes

  1. Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit

    Serious TEAEs are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment and additionally are emergent untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalisation or prolongation of existing hospitalisation * Results in persistent disability/incapacity * Is a congenital anomaly or birth defect * Important medical events

    Time frame: From Baseline up to the EOS Visit (up to 52 weeks)

  2. Occurrence of TEAEs leading to permanent withdrawal of IMP up to the EOS Visit

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Baseline up to the EOS Visit (up to 52 weeks)

  3. Occurrence of Adverse Event(s) of Special Monitoring (AESM) up to the EOS Visit

    AESMs are: Severe and/or serious headache, suspected aseptic meningitis, severe Gastrointestinal (GI) disorders, and opportunistic infection.

    Time frame: From Baseline up to the EOS Visit (up to 52 weeks)

Secondary outcomes

  1. Percent change in total Immunoglobulin G (IgG) from Baseline to the end of Week 6 of each Treatment Period (TP)

    Plasma concentration analyses of total IgG will be done for all study participants on an ongoing basis to the end of Week 6 of each TP.

    Time frame: From Baseline to the end of Week 6 of each TP (up to 52 weeks)

  2. Absolute change in total IgG from Baseline to the end of Week 6 of each TP

    Plasma concentration analyses of total IgG will be done for all study participants on an ongoing basis to the end of Week 6 of each TP.

    Time frame: From Baseline to the end of Week 6 of each TP (up to 52 weeks)

  3. Change from Baseline in Myasthenia Gravis-Activities of Daily Living (MG ADL) total score at the end of Week 6 of each TP

    The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.

    Time frame: From Baseline to the end of Week 6 of each TP (up to 52 weeks)

  4. Change from Baseline in Quantitative Myasthenia Gravis (QMG) total score at the end of Week 6 of each TP

    QMG score is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The QMG total score is obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity.

    Time frame: From Baseline to the end of Week 6 of each TP (up to 52 weeks)

07

Study locations

9 sites
  • Mg0008 40290
    Bologna, Italy
  • Mg0008 40144
    Milan, Italy
  • Mg0008 40733
    Naples, Italy
  • Mg0008 20340
    Fuchu-shi, Japan
  • Mg0008 20339
    Ōbu, Japan
  • Mg0008 20343
    Sagamihara, Japan
  • Mg0008 40734
    Lodz, Poland
  • Mg0008 40155
    Warsaw, Poland
  • Mg0008 40841
    Yenimahalle, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 35 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2027 → Oct 2027 and completion Aug 2027 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Aug 6, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Oct 5, 2027was Aug 2027
CompletionEst.
Oct 5, 2027was Aug 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 16, 2026
Sites
2 sites removed; no longer in Taiwan
Show 2 removed
  • Mg0008 20081 · Taipei, Taiwan
  • Mg0008 20095 · Taipei, Taiwan
Oct 27, 2026
Primary completion
Aug 17, 2027→Oct 5, 2027
Oct 16, 2026
Study completion
Aug 17, 2027→Oct 5, 2027
Oct 16, 2026
Enrollment
12 (estimated)→13 (actual)
Oct 16, 2026
Show all 3 updates
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 27, 2026
    2 sites removed; no longer in Taiwan
    Show 2 removed
    • Mg0008 20081 · Taipei, Taiwan
    • Mg0008 20095 · Taipei, Taiwan
  3. Oct 16, 2026
    Enrolling by invitation→Active, not recruiting
    Primary completion Aug 17, 2027→Oct 5, 2027
    Study completion Aug 17, 2027→Oct 5, 2027
    Enrollment 12 (estimated)→13 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06540144
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 6, 2024
Start date
Oct 8, 2024
Primary completion
Oct 5, 2027 (estimated)
Completion
Oct 5, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion